Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

343 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Physiologically-based pharmacokinetic model-based translation of OATP1B-mediated drug-drug interactions from coproporphyrin I to probe drugs.
Mochizuki T, Aoki Y, Yoshikado T, Yoshida K, Lai Y, Hirabayashi H, Yamaura Y, Rockich K, Taskar K, Takashima T, Chu X, Zamek-Gliszczynski MJ, Mao J, Maeda K, Furihata K, Sugiyama Y, Kusuhara H. Mochizuki T, et al. Among authors: furihata k. Clin Transl Sci. 2022 Jun;15(6):1519-1531. doi: 10.1111/cts.13272. Epub 2022 May 2. Clin Transl Sci. 2022. PMID: 35421902 Free PMC article.
Quantitative Analyses of the Influence of Parameters Governing Rate-Determining Process of Hepatic Elimination of Drugs on the Magnitudes of Drug-Drug Interactions via Hepatic OATPs and CYP3A Using Physiologically Based Pharmacokinetic Models.
Yoshikado T, Maeda K, Kusuhara H, Furihata KI, Sugiyama Y. Yoshikado T, et al. Among authors: furihata ki. J Pharm Sci. 2017 Sep;106(9):2739-2750. doi: 10.1016/j.xphs.2017.05.001. Epub 2017 May 8. J Pharm Sci. 2017. PMID: 28495568
Effect of Cyclosporin A and Impact of Dose Staggering on OATP1B1/1B3 Endogenous Substrates and Drug Probes for Assessing Clinical Drug Interactions.
Mochizuki T, Zamek-Gliszczynski MJ, Yoshida K, Mao J, Taskar K, Hirabayashi H, Chu X, Lai Y, Takashima T, Rockich K, Yamaura Y, Fujiwara K, Mizuno T, Maeda K, Furihata K, Sugiyama Y, Kusuhara H. Mochizuki T, et al. Among authors: furihata k. Clin Pharmacol Ther. 2022 Jun;111(6):1315-1323. doi: 10.1002/cpt.2584. Epub 2022 Apr 11. Clin Pharmacol Ther. 2022. PMID: 35292967 Free PMC article.
Dose-Dependent Inhibition of OATP1B by Rifampicin in Healthy Volunteers: Comprehensive Evaluation of Candidate Biomarkers and OATP1B Probe Drugs.
Mori D, Kimoto E, Rago B, Kondo Y, King-Ahmad A, Ramanathan R, Wood LS, Johnson JG, Le VH, Vourvahis M, David Rodrigues A, Muto C, Furihata K, Sugiyama Y, Kusuhara H. Mori D, et al. Among authors: furihata k. Clin Pharmacol Ther. 2020 Apr;107(4):1004-1013. doi: 10.1002/cpt.1695. Epub 2020 Jan 1. Clin Pharmacol Ther. 2020. PMID: 31628668 Free PMC article. Clinical Trial.
Investigation of Glycochenodeoxycholate Sulfate and Chenodeoxycholate Glucuronide as Surrogate Endogenous Probes for Drug Interaction Studies of OATP1B1 and OATP1B3 in Healthy Japanese Volunteers.
Takehara I, Terashima H, Nakayama T, Yoshikado T, Yoshida M, Furihata K, Watanabe N, Maeda K, Ando O, Sugiyama Y, Kusuhara H. Takehara I, et al. Among authors: furihata k. Pharm Res. 2017 Aug;34(8):1601-1614. doi: 10.1007/s11095-017-2184-5. Epub 2017 May 26. Pharm Res. 2017. PMID: 28550384
Identification of Appropriate Endogenous Biomarker for Risk Assessment of Multidrug and Toxin Extrusion Protein-Mediated Drug-Drug Interactions in Healthy Volunteers.
Miyake T, Kimoto E, Luo L, Mathialagan S, Horlbogen LM, Ramanathan R, Wood LS, Johnson JG, Le VH, Vourvahis M, Rodrigues AD, Muto C, Furihata K, Sugiyama Y, Kusuhara H. Miyake T, et al. Among authors: furihata k. Clin Pharmacol Ther. 2021 Feb;109(2):507-516. doi: 10.1002/cpt.2022. Epub 2020 Oct 9. Clin Pharmacol Ther. 2021. PMID: 32866300 Free PMC article. Clinical Trial.
343 results